$32.54
1.74%
NYSE, Apr 21, 08:50 pm CET
ISIN
US03770N1019
Symbol
APGE
Sector
Industry

Apogee Therapeutics Stock price

$33.11
-7.24 17.94% 1M
-23.12 41.12% 6M
-12.19 26.91% YTD
-18.39 35.71% 1Y
+11.88 55.96% 3Y
+11.88 55.96% 5Y
+11.88 55.96% 10Y
NYSE, Closing price Thu, Apr 17 2025
+1.07 3.34%
ISIN
US03770N1019
Symbol
APGE
Sector
Industry

Key metrics

Market capitalization $1.97b
Enterprise Value $1.46b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.75
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-216.87m
Free Cash Flow (TTM) Free Cash Flow $-172.33m
Cash position $520.65m
EPS (TTM) EPS $-3.23
P/E forward negative
Short interest 21.66%
Show more

Is Apogee Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Apogee Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Apogee Therapeutics forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Apogee Therapeutics forecast:

Buy
100%

Financial data from Apogee Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.19 0.19
-
-
-0.19 -0.19
-
-
- Selling and Administrative Expenses 49 49
98% 98%
-
- Research and Development Expense 168 168
145% 145%
-
-217 -217
133% 133%
-
- Depreciation and Amortization 0.19 0.19
-
-
EBIT (Operating Income) EBIT -217 -217
133% 133%
-
Net Profit -182 -182
117% 117%
-

In millions USD.

Don't miss a Thing! We will send you all news about Apogee Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Apogee Therapeutics Stock News

Positive
Seeking Alpha
7 days ago
Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious pipeline development in inflammatory diseases. Significant R&D investments in lead IL-13 inhibitor APG777 and combination therapies reflect a strategic push for differentiated, best-in-class treatments in atopic dermatitis and asthma. Encouraging Phase 1 data for OX40L inh...
Neutral
GlobeNewsWire
about 2 months ago
Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025
Neutral
GlobeNewsWire
about 2 months ago
Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life
More Apogee Therapeutics News

Company Profile

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in February 2022 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Henderson
Employees 196
Founded 2022
Website www.apogeetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today